ZA200809493B - Method of treatment of age-related macular degeneration (AMD) - Google Patents
Method of treatment of age-related macular degeneration (AMD)Info
- Publication number
- ZA200809493B ZA200809493B ZA200809493A ZA200809493A ZA200809493B ZA 200809493 B ZA200809493 B ZA 200809493B ZA 200809493 A ZA200809493 A ZA 200809493A ZA 200809493 A ZA200809493 A ZA 200809493A ZA 200809493 B ZA200809493 B ZA 200809493B
- Authority
- ZA
- South Africa
- Prior art keywords
- amd
- age
- treatment
- macular degeneration
- related macular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79227806P | 2006-04-14 | 2006-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200809493B true ZA200809493B (en) | 2010-08-25 |
Family
ID=38608967
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200809493A ZA200809493B (en) | 2006-04-14 | 2007-04-13 | Method of treatment of age-related macular degeneration (AMD) |
ZA2010/05922A ZA201005922B (en) | 2006-04-14 | 2010-08-19 | Method of treatment of age-related macular degeneration (amd) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2010/05922A ZA201005922B (en) | 2006-04-14 | 2010-08-19 | Method of treatment of age-related macular degeneration (amd) |
Country Status (14)
Country | Link |
---|---|
US (3) | US20100144693A1 (de) |
EP (2) | EP2012789B1 (de) |
JP (1) | JP5290147B2 (de) |
KR (2) | KR20080109096A (de) |
CN (3) | CN102225930A (de) |
AU (2) | AU2007240120A1 (de) |
BR (2) | BRPI0710737A2 (de) |
CA (1) | CA2683756A1 (de) |
DK (1) | DK2012789T3 (de) |
ES (1) | ES2437997T3 (de) |
IL (1) | IL207495A (de) |
NZ (2) | NZ572591A (de) |
WO (1) | WO2007118276A1 (de) |
ZA (2) | ZA200809493B (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
CA2609659C (en) | 2005-05-26 | 2014-01-28 | Neuron Systems, Inc. | Azanaphthalenes, compositions and methods for treating retinal disease |
DK2044026T3 (da) * | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
JP2011530596A (ja) * | 2008-08-11 | 2011-12-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | tRNA合成酵素の阻害のためのハロフジノン類似体およびそれらの使用 |
US8889695B2 (en) * | 2008-12-24 | 2014-11-18 | Prana Biotechnology Limited | Quinazolinone compounds |
BRPI0920492A2 (pt) | 2009-01-26 | 2019-07-09 | Lawrence Dunaief Joshua | uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. |
WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
WO2012122534A2 (en) | 2011-03-10 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation |
AU2013207796B2 (en) | 2012-01-13 | 2017-04-27 | President And Fellows Of Harvard College | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
MX2015007916A (es) | 2012-12-20 | 2016-04-07 | Aldeyra Therapeutics Inc | Peri-carbinoles. |
AU2014209387B2 (en) | 2013-01-23 | 2018-11-01 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
EP2948436A4 (de) | 2013-01-25 | 2016-07-13 | Aldeyra Therapeutics Inc | Neuartige fallen bei der behandlung von makuladegeneration |
BR112017011335A2 (pt) * | 2014-12-02 | 2018-02-20 | Prana Biotechnology Limited | compostos de 4h-pirido[1,2-a]pirimidin-4-ona |
JP2018514817A (ja) * | 2015-04-29 | 2018-06-07 | トライアペックス カンパニー リミテッド | 偏光フィルム、その製造方法、およびこれを含む偏光レンズ |
US10781178B2 (en) * | 2015-08-12 | 2020-09-22 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
CA2996183A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
US11008290B2 (en) * | 2015-09-24 | 2021-05-18 | University Of Florida Research Foundation, Incorporated | Halogenated quinoline derivatives as antimicrobial agents |
JP7116490B2 (ja) | 2016-05-09 | 2022-08-10 | アルデイラ セラピューティクス, インコーポレイテッド | 眼の炎症性障害および疾患の組合せ処置 |
WO2018000047A1 (en) * | 2016-07-01 | 2018-01-04 | Prana Biotechnology Limited | Method of treating immunoglobulin light chain amyloidosis |
US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
US11708353B2 (en) | 2018-06-08 | 2023-07-25 | The General Hospital Corporation | Inhibitors of prolyl-tRNA-synthetase |
WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
CN109232396B (zh) * | 2018-11-27 | 2020-07-03 | 聊城大学 | 酰胺吡啶类衍生物及其用途 |
JP2023532134A (ja) * | 2020-07-02 | 2023-07-26 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 網膜変性の処置において使用するための環式化合物 |
CN113214249B (zh) * | 2021-04-23 | 2023-09-19 | 成都大学 | 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE505711A (de) | 1950-09-09 | |||
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
HU178910B (en) * | 1977-08-19 | 1982-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
IT1204612B (it) | 1987-05-14 | 1989-03-10 | Bioresearch Spa | Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica |
US5314909A (en) * | 1993-03-17 | 1994-05-24 | Merck & Co., Inc. | Use of non-steroidal antiiflammatory agents in macular degeneration |
AU674402B2 (en) | 1993-04-08 | 1996-12-19 | Ideal-Standard Gmbh | Sanitary water tap |
US5631373A (en) | 1993-11-05 | 1997-05-20 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
DE4418096A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase |
US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
PL188838B1 (pl) * | 1996-08-13 | 2005-04-29 | P N Gerolymatos Sa | Zastosowanie kliochinolu do wytwarzania środka farmaceutycznego i środek farmaceutyczny |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
NZ510098A (en) | 1998-10-22 | 2003-09-26 | Neurosearch As | Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel |
US6369058B1 (en) * | 1999-02-04 | 2002-04-09 | New Millennium Pharmaceutical Research Inc. | Brain delivery of folic acid for the prevention of alzheimer's disease and stroke |
AU7080500A (en) | 1999-08-27 | 2001-03-26 | Chemocentryx, Inc. | Compounds and methods for modulating cxcr3 function |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
ATE528303T1 (de) | 2000-12-21 | 2011-10-15 | Vertex Pharma | Pyrazoleverbindungen als proteinkinasehemmer |
FR2819187A1 (fr) | 2001-01-10 | 2002-07-12 | Michel Xilinas | Utilisation des substances chelatrices pour le traitement et la prevention de la deferrescence oculaire |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
US20050014780A1 (en) | 2001-08-17 | 2005-01-20 | Maligres Peter E. | Process for preparing 5-sulfonamido-8-hydroxy-1,6-naphthyridine-7-carboxamides |
AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
AU2003228283A1 (en) | 2002-03-07 | 2003-09-22 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
KR101122782B1 (ko) * | 2002-10-04 | 2012-04-12 | 프라나 바이오테크놀로지 리미티드 | 신경 활성 화합물 |
CN1791408A (zh) * | 2003-04-03 | 2006-06-21 | 普拉纳生物技术有限公司 | 神经系统疾病的治疗 |
UA96115C2 (uk) * | 2003-06-23 | 2011-10-10 | Беллас Хелс (Інтернешнл) Лімітед | Спосіб і композиція для лікування амілоїдогенних захворювань |
CA2563038C (en) * | 2004-04-02 | 2013-10-29 | Gaik Beng Kok | Neurologically-active compounds |
WO2006083533A2 (en) * | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
WO2006117660A2 (en) * | 2005-05-04 | 2006-11-09 | Clio Pharmaceutical Corporation | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins |
DK2044026T3 (da) * | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
-
2007
- 2007-04-13 CA CA002683756A patent/CA2683756A1/en not_active Abandoned
- 2007-04-13 AU AU2007240120A patent/AU2007240120A1/en not_active Abandoned
- 2007-04-13 JP JP2009504530A patent/JP5290147B2/ja not_active Expired - Fee Related
- 2007-04-13 BR BRPI0710737-4A patent/BRPI0710737A2/pt not_active IP Right Cessation
- 2007-04-13 EP EP07718737.5A patent/EP2012789B1/de not_active Not-in-force
- 2007-04-13 CN CN2011101585377A patent/CN102225930A/zh active Pending
- 2007-04-13 ZA ZA200809493A patent/ZA200809493B/xx unknown
- 2007-04-13 KR KR1020087027935A patent/KR20080109096A/ko not_active Application Discontinuation
- 2007-04-13 DK DK07718737.5T patent/DK2012789T3/da active
- 2007-04-13 CN CNA2007800222734A patent/CN101534826A/zh active Pending
- 2007-04-13 US US12/297,165 patent/US20100144693A1/en not_active Abandoned
- 2007-04-13 BR BRPI0722382-0A patent/BRPI0722382A2/pt not_active Application Discontinuation
- 2007-04-13 EP EP12176495A patent/EP2514423A3/de not_active Withdrawn
- 2007-04-13 ES ES07718737.5T patent/ES2437997T3/es active Active
- 2007-04-13 KR KR1020107020805A patent/KR20100110396A/ko not_active Application Discontinuation
- 2007-04-13 NZ NZ572591A patent/NZ572591A/en not_active IP Right Cessation
- 2007-04-13 NZ NZ590271A patent/NZ590271A/en unknown
- 2007-04-13 WO PCT/AU2007/000490 patent/WO2007118276A1/en active Application Filing
- 2007-04-13 CN CN2010102559981A patent/CN101987849B/zh not_active Expired - Fee Related
-
2010
- 2010-07-30 AU AU2010206074A patent/AU2010206074B2/en not_active Ceased
- 2010-08-09 IL IL207495A patent/IL207495A/en active IP Right Grant
- 2010-08-19 ZA ZA2010/05922A patent/ZA201005922B/en unknown
- 2010-11-23 US US12/952,425 patent/US20110071167A1/en not_active Abandoned
-
2013
- 2013-11-22 US US14/087,689 patent/US9163018B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2012789A4 (de) | 2011-02-16 |
CN101987849B (zh) | 2013-05-08 |
AU2010206074A1 (en) | 2010-08-19 |
JP2009533356A (ja) | 2009-09-17 |
EP2514423A2 (de) | 2012-10-24 |
CN102225930A (zh) | 2011-10-26 |
ZA201005922B (en) | 2013-09-25 |
BRPI0722382A2 (pt) | 2012-06-05 |
NZ572591A (en) | 2012-01-12 |
AU2007240120A2 (en) | 2008-12-18 |
EP2514423A3 (de) | 2012-12-19 |
ES2437997T3 (es) | 2014-01-15 |
NZ590271A (en) | 2011-12-22 |
US9163018B2 (en) | 2015-10-20 |
EP2012789B1 (de) | 2013-09-25 |
US20100144693A1 (en) | 2010-06-10 |
BRPI0710737A2 (pt) | 2011-05-10 |
US20140088122A1 (en) | 2014-03-27 |
IL207495A (en) | 2015-05-31 |
CA2683756A1 (en) | 2007-10-25 |
CN101534826A (zh) | 2009-09-16 |
KR20100110396A (ko) | 2010-10-12 |
CN101987849A (zh) | 2011-03-23 |
DK2012789T3 (da) | 2013-12-16 |
AU2010206074B2 (en) | 2012-08-30 |
US20110071167A1 (en) | 2011-03-24 |
AU2007240120A1 (en) | 2007-10-25 |
EP2012789A1 (de) | 2009-01-14 |
WO2007118276A1 (en) | 2007-10-25 |
JP5290147B2 (ja) | 2013-09-18 |
IL207495A0 (en) | 2010-12-30 |
KR20080109096A (ko) | 2008-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201005922B (en) | Method of treatment of age-related macular degeneration (amd) | |
EP2089016A4 (de) | Verfahren zur behandlung von makuladegeneration | |
EP2017227A4 (de) | Verfahren zur bearbeitung arsenhaltiger lösungen | |
EP2032131A4 (de) | Behandlungsverfahren | |
GB0610746D0 (en) | Method of treatment | |
PL2252317T3 (pl) | Leczenie zwyrodnienia plamki żółtej | |
EP2187880A4 (de) | Zusammensetzungen und verfahren zur behandlung von makuladegeneration | |
DK2044223T3 (da) | Diagnosticering og behandling af aldersrelateret makuladegeneration | |
GB0510196D0 (en) | Composition for treatment of a detached retina and method of production thereof | |
EP2046366A4 (de) | Verfahren zur behandlung von altersbedingter makuladegeneration | |
EP1855729A4 (de) | Sterilisierverfahren | |
ZA201008201B (en) | Novel compositions and methods for treating hyperproliferative diseases | |
IL173971A0 (en) | Compositions and methods for treating and preventing age-related macular degeneration | |
WO2007098122A3 (en) | Methods for the treatment of macular degeneration and related eye conditions | |
PL2061501T3 (pl) | Sposób leczenia zaburzeń oddechowych | |
EP2252895A4 (de) | Verfahren und zusammensetzungen zur diagnose altersbedingter makuladegeneration | |
ZA200707420B (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
EP2083841A4 (de) | Behandlung für altersbedingte makuladegeneration und andere augenleiden | |
GB0625844D0 (en) | The treatment of macular degeneration | |
EP2194793A4 (de) | Verfahren zur behandlung von frischen agrarprodukten | |
IL213550A0 (en) | Method for treating macular degeneration | |
GB0501129D0 (en) | Method of treatment by administration of RNA | |
EP1971358A4 (de) | Behandlungsverfahren | |
GB0713367D0 (en) | Apparatus amd method of treating filter elements | |
EP2203432A4 (de) | Behandlungsverfahren |